Trilaciclib Impurity 35

Tert-butyl 4-methylsulfanyl-10-oxospiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate

pharmaceutical intermediate

Benzyl (2S)-2-{8-aminoimidazo[1,5-a]pyrazin-3-yl}pyrrolidine-1-carboxylate

Pharmaceutical intermediate for impurity synthesis

Fmoc-Ile-Aib-OH

Peptide building block for synthesis

((3aS,5R,6S,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(morpholino)methanone

Pharmaceutical intermediate for SGLT2 inhibitors

((((E)-2-((2R,3R,4R,5R)-3-(((2-CYANOETHOXY)(DIISOPROPYLAMINO)PHOSPHINO)OXY)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)-4-METHOXYTETRAHYDROFURAN-2-YL)VINYL)PHOSPHORYL)BIS(OXY))BIS(METHYLENE) BIS(2,2-DIMETHYLPROPANOATE)

nucleoside phosphoramidite for oligonucleotide synthesis

Tert-butyl 8-hydroxy-4-methylsulfanyl-10-oxo-spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-11-carboxylate

Pharmaceutical intermediate for kinase inhibitors

Trilaciclib Impurity 36

pharmaceutical intermediate synthesis

Trilaciclib Impurity 3

Pharmaceutical impurity reference standard